홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
GPCR
#1522
Structure Therapeutics Inc. American Depositary Shares
53.220
0
USD
-1.90%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
-1.90%
월간 변동
-5.39%
6달 변화
+99.03%
년간 변동율
+99.03%
이전 종가
54.250
0
Open
53.194
0
Bid
Ask
Low
53.194
0
High
53.220
0
양
73
마켓
주식
헬스케어
GPCR
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2023
2024
2025
TTM
Key stats
Total common shares outstanding
46.6 M
57.34 M
70.84 M
—
Valuation ratios
Enterprise value
1.75 B
1.39 B
4.13 B
7.61 B
Price to earnings ratio
-49.86
-34.77
-86.94
-149.54
Price to sales ratio
—
—
—
—
Price to cash flow ratio
-55.99
-36.72
-55.59
-122.51
Price to book ratio
9.83
4.95
8.15
11.44
EBITDA 비율에 대한 기업 가치
—
—
—
—
Profitability ratios
Return on assets %
-0.19
-0.14
-0.09
-0.19
Return on equity %
-0.2
-0.14
-0.09
-0.2
Return on invested capital %
-2 026.88
-2 721.03
-1 075.54
-2 178.26
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
19.14
24.74
24.81
82.73
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.72
-0.74
-1.25
-1.27
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
4.24
5.59
8.14
22.12
Net current asset value per share
4.3
5.64
8.84
23.06
Tangible book value per share
4.11
5.48
8.54
22.2
Working capital per share
4.07
5.42
8.49
21.93
Book value per share
4.11
5.48
8.54
22.2
뉴스
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster (GPCR)
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
BMO, 스트럭처 테라퓨틱스 목표 주가 상향… 비만 치료제 데이터 호평
BMO raises Structure Therapeutics stock price target on obesity drug data
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target (GPCR)
일라이릴리 경쟁사, Structure Therapeutics 목표가 하향
H.C. Wainwright lowers Structure Therapeutics price target on penetration assumptions
스트럭처 테라퓨틱스, 체중 감량 데이터에 강세 유지